StockWireNews

Biotech Breakout Tuesday: (ANIX) Is Backed By 10+ Triggered Technical Indicators (Analysts Lick Their Lips)

January 15th

Greetings Readers,

A new multi-month high? A double-digit intraday surge?

That's what happened this past Thursday with my latest breakout idea.

Surging from an initial opening at $2.18 to reach a peak of $2.67, the Nasdaq tech profile executed a remarkably dynamic intraday surge, registering an impressive move of approx. 22%.

Solid stuff, but it gets even better when you realize that was our 5th straight champ in a row!

With recent runners of approximately 19%, 19%, 95%, and 39%, this streak has been bringing the heat all winter while everyone has been freezing their butts off!

Ready to turn it up a few degrees?

Well, when it comes to red hot technicals, this breakout idea has got them.

With at least 10 triggered across the short, medium, and long term over at Barchart, this moderately low float (29.6Mn shares) profile is starting to turn heads.

But that's not all...

Focused on developing immunotherapy treatments for breast and ovarian cancers, this biotechnology company has recently disclosed positive results stemming from the Phase 1 clinical trial of its breast cancer vaccine.

And how about 2 analyst targets that suggest over 100+% potential upside from current levels?

You're officially on the clock to pull up:

*Anixa Biosciences, Inc. (ANIX)*

Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer.

Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology.

The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer.

And based on these glaring potential catalysts, ANIX could be set to take the breakout stage. Check them out:

#1. Bullish Technical Indicators (At Least 10 Triggered This Moment).

#2. Game-Changing News Comes In The Form Of Positive Phase 1 Study Data.

#3. Analyst Targets Suggest Triple-Digit Upside Potential From Current Levels.

But more on those in a second...

Anixa Snapshot

Clinical-stage company developing first-in-class products to treat & prevent cancer.

Anixa Biosciences, Inc. is developing therapies and vaccines that are focused on critical unmet needs in oncology.

Anixa’s programs are using the body’s immune system to take multiple approaches in fighting cancer—CAR-T cell therapy to treat cancer and vaccines to prevent cancer.

Therapeutics

CAR-T

Anixa is developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.

Vaccines

Breast Cancer Vaccine

The company is developing a revolutionary vaccine technology focused on preventing breast cancer, specifically triple negative breast cancer, the most lethal form of the disease.

Ovarian Cancer Vaccine

Using a similar mechanism of action as our breast cancer vaccine technology, the company is developing a vaccine to prevent the occurrence of ovarian cancer.

Today's ANIX Focus: Pre-Clinical Studies

Vaccination Prevents Breast Cancer

Phase 1 Trial - Conducted by Cleveland Clinic, fund-ed by U.S. Department of Defense (DOD)

An open-label Phase 1 dose-escalation trial

Design: Participants will receive three vaccinations, each two weeks apart, and will be closely monitored for side effects and immune response

Phase 1a (in progress):

• 18-24 Patients who have been treated for TNBC
• Safety will be monitored
• Immune Response will be monitored
• Maximum Tolerated Dose (“MTD”) determined

Phase 1b (enrollment open):

• Healthy women w/mutations
• Chosen to undergo prophylactic mastectomy
• Vaccinate before surgery and evaluate immune response and resected tissue
• Unique opp. to garner supplemental data after studying breast tissue to determine if T cells are surveilling the tissue without any visible cancer tumors

Phase 1c (enrollment open):

• Additional cohort combining vaccine with Keytruda
• Patients treated for TNBC
• Combine Keytruda w/ vaccine to evaluate if there is synergy
  

Breast Cancer Vaccine: A Significant Market Opp.

Successive to appropriate clinical trials, a prophylactic (preventative) vaccines may be eventually administered to the total eligible population.

Multi-Bn Dollar Market opp.

1) National Cancer Institute

If this vaccine works as the company hopes and expects, every woman in the world may be eligible!

Anixa's Product Pipeline

Sources: Company Website. Company Presentation.

-----

Though that fills you in on the incredible company moves that ANIX is up to currently, it doesn't get to the heart of what we need to focus on right this second.

*Here Are The Most Pressing Potential Catalysts ANIX Is Working With...

#1. Bullish Technical Indicators (At Least 10 Triggered This Moment).

At close on Friday, Barchart was reporting ANIX to have a multitude of bullish technical indicators across the short, medium, and long term.

Here's a quick list:

Short Term Indicators

• 20 Day Moving Average
• 20 - 50 Day MACD Oscillator
• 20 - 100 Day MACD Oscillator
• 20 - 200 Day MACD Oscillator

Medium Term Indicators

• 50 Day Moving Average
• 50 - 100 Day MACD Oscillator
• 50 - 150 Day MACD Oscillator

Long Term Indicators

• 100 Day Moving Average
• 150 Day Moving Average
• 200 Day Moving Average

Not only those, but Barchart's composite "Trend Seeker" indicator is triggered, too.

#2. Game-Changing News Comes In The Form Of Positive Phase 1 Study Data.

Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences stated: "The data from our Phase 1 trial to date has exceeded our expectations, and we are pleased with our progress. This vaccine is designed to direct the immune system to destroy TNBC cancer cells through a mechanism that has never previously been utilized for cancer vaccine development."

#3. Analyst Targets Suggest Triple-Digit Upside Potential From Current Levels.

Last, but no least, at least 2 different analysts have painted rosy targets on ANIX. Take a look at what MarketBeat has to share:

From Friday's closing valuation, these two targets represent over a 100+% potential upside!

Could it be time to stop sleeping on Anixa Biosciences, Inc. (ANIX)?

Time is officially ticking to get ANIX on radar now. When updates pop up, I'll have them out to you quickly this week.

Sincerely,

Kai Parker

StockWireNews

(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)